Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.

Asian Pacific journal of cancer prevention : APJCP - 1 Jul 2026

Melinkeri Sameer, Dhawan Rishi, Garg Jeevan Kumar, Kulkarni Uday

Abstract excerpt

OBJECTIVE: Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy in which cytogenetic and molecular abnormalities critically influence prognosis and treatment decisions. Since the identification of isocitrate dehydrogenase (IDH) mutations in AML in 2009, growing evidence has highlighted their role in leukemogenesis through aberrant cellular metabolism and epigenetic dysregulation....

Topics

Join the communities discussing this publication.

Antineoplastic Agents
DNMT3A gene
India
Isocitrate Dehydrogenase
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 42522802
DOI: 10.31557/APJCP.2026.27.7.2417

Genes

IDH1
DNMT3A
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.PMID 42522802Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

IDH1/2 mutations in acute myeloid leukemiaSemantic proximity Read ↗

IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Semantic proximity Read ↗

Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.Semantic proximity Read ↗

Evaluating ivosidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.